Fernie-King Barbara A, Seilly David J, Davies Alexandra, Lachmann Peter J
Microbial Immunology Group, Centre for Veterinary Science, University of Cambridge, Cambridge, United Kingdom.
Infect Immun. 2002 Sep;70(9):4908-16. doi: 10.1128/IAI.70.9.4908-4916.2002.
Streptococcal inhibitor of complement (SIC) is a 31-kDa extracellular protein of a few, very virulent, strains of Streptococcus pyogenes (particularly M1 strains). It is secreted in large quantities (about 5 mg/liter) and inhibits complement lysis by blocking the membrane insertion site on C5b67. We describe investigations into the interaction of SIC with three further major components of the innate immune system found in airway surface liquid, namely, secretory leukocyte proteinase inhibitor (SLPI), lysozyme, and lactoferrin. Enzyme-linked immunosorbent assays showed that SIC binds to SLPI and to both human and hen egg lysozyme (HEL) but not to lactoferrin. Studies using (125)I-labeled proteins showed that SIC binds approximately two molecules of SLPI and four molecules of lysozyme. SLPI binding shows little temperature dependence and a small positive enthalpy, suggesting that the binding is largely hydrophobic. By contrast, lysozyme binding shows strong temperature dependence and a substantial negative enthalpy, suggesting that the binding is largely ionic. Lysozyme is precipitated from solution by SIC. Further studies examined the ability of SIC to block the biological activities of SLPI and lysozyme. An M1 strain of group A streptococci was killed by SLPI, and the antibacterial activity of this protein was inhibited by SIC. SIC did not inhibit the antiproteinase activity of SLPI, implying that there is specific inhibition of the antibacterial domain. The antibacterial and enzymatic activities of lysozyme were also inhibited by SIC. SIC is the first biological inhibitor of the antibacterial action of SLPI to be described and may prove to be an important tool for investigating this activity in vivo. Inhibition of the antibacterial actions of SLPI and lysozyme would be advantageous to S. pyogenes in establishing colonization on mucosal surfaces, and we propose that this is the principal function of SIC.
补体链球菌抑制剂(SIC)是化脓性链球菌少数高毒力菌株(特别是M1菌株)分泌的一种31 kDa的细胞外蛋白。它大量分泌(约5毫克/升),通过阻断C5b67的膜插入位点来抑制补体裂解。我们描述了对SIC与气道表面液体中发现的先天免疫系统另外三个主要成分相互作用的研究,即分泌型白细胞蛋白酶抑制剂(SLPI)、溶菌酶和乳铁蛋白。酶联免疫吸附测定表明,SIC与SLPI以及人溶菌酶和鸡卵溶菌酶(HEL)结合,但不与乳铁蛋白结合。使用(125)I标记蛋白的研究表明,SIC结合大约两个分子的SLPI和四个分子的溶菌酶。SLPI结合对温度依赖性较小且焓变为小的正值,表明结合主要是疏水性的。相比之下,溶菌酶结合表现出强烈的温度依赖性和显著的负焓变,表明结合主要是离子性的。溶菌酶可被SIC从溶液中沉淀出来。进一步的研究考察了SIC阻断SLPI和溶菌酶生物学活性的能力。A组链球菌的M1菌株可被SLPI杀灭,而该蛋白的抗菌活性被SIC抑制。SIC不抑制SLPI的抗蛋白酶活性,这意味着对抗菌结构域存在特异性抑制。溶菌酶的抗菌和酶活性也被SIC抑制。SIC是所描述的第一种SLPI抗菌作用的生物抑制剂,可能被证明是体内研究该活性的重要工具。抑制SLPI和溶菌酶的抗菌作用对化脓性链球菌在粘膜表面建立定植是有利的,我们认为这是SIC的主要功能。